Jan 23 (Reuters) - Vigil Neuroscience Inc VIGL.O:
VIGIL NEUROSCIENCE REPORTS POSITIVE DATA FROM ITS PHASE 1 CLINICAL TRIAL EVALUATING VG-3927 FOR THE POTENTIAL TREATMENT OF ALZHEIMER’S DISEASE
VIGIL NEUROSCIENCE INC - VG-3927 TO ADVANCE TO PHASE 2 TRIAL IN Q3 2025
VIGIL NEUROSCIENCE INC - VG-3927 ACHIEVED UP TO 50% REDUCTION OF STREM2 IN CSF
VIGIL NEUROSCIENCE INC - VG-3927 SHOWED FAVORABLE SAFETY AND TOLERABILITY PROFILE
Source text: ID:nGNXqgh0d
Further company coverage: VIGL.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.